Study of the efficacy, tolerability, and safety of 2 fixed-dose combination gels in the management of acne vulgaris.

摘要: This study investigated the efficacy, tolerability, and safety of 2 fixed-dose combination gels for treatment facial acne: clindamycin 1%-benzoyl peroxide 5% gel with hydrating excipients (C/BPO HE) adapalene 0.1%-benzoyl 25% (A/BPO). After 12 weeks once daily treatment, mean reduction in inflammatory lesion count was 76.8% 72.2% C/BPO HE group A/BPO group, respectively (P = .076). Significantly more participants achieved success, which defined as an improvement grades or from baseline to week on investigator's static global assessment (ISGA) scale, (30.5% [58/190]) compared (21.8% [42/192]) .046), success quickly .035). Both products also reduced noninflammatory (62.2% vs 6 1.5% A/BPO) total counts (69.1% 67.1% A/BPO). Despite overall similar efficacy profile, better tolerated safer than A/BPO. In tolerability assessments, erythema, dryness, peeling, pruritus, burning/ stinging were frequent at all time points 1 onward < .05). Treatment-related adverse events (AEs) occurred 48.4% (92/190) 78.6% (151/192) group. We conclude that have treating acne lesions, but achieves less coupled a significantly profile notably profile.